Creative Financial Designs’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $50.8K | Buy |
397
+78
| +24% | +$9.74K | ﹤0.01% | 890 |
|
|
2025
Q4 | $39K | Buy |
+319
| New | +$36.6K | ﹤0.01% | 952 |
|
|
2025
Q2 | – | Sell |
-29
| Closed | -$2.35K | – | 2183 |
|
|
2025
Q1 | $2.35K | Sell |
29
-111
| -79% | -$9.92K | ﹤0.01% | 1642 |
|
|
2024
Q4 | $12.6K | Hold |
140
| – | – | ﹤0.01% | 1163 |
|
|
2024
Q3 | $13.8K | Buy |
140
+64
| +84% | +$6.29K | ﹤0.01% | 1112 |
|
|
2024
Q2 | $7.05K | Sell |
76
-178
| -70% | -$16K | ﹤0.01% | 1250 |
|
|
2024
Q1 | $24.1K | Sell |
254
-1,356
| -84% | -$126K | ﹤0.01% | 920 |
|
|
2023
Q4 | $144K | Buy |
1,610
+1,427
| +780% | +$106K | 0.01% | 459 |
|
|
2023
Q3 | $13.4K | Hold |
183
| – | – | ﹤0.01% | 951 |
|
|
2023
Q2 | $15.2K | Sell |
183
-67
| -27% | -$5.6K | ﹤0.01% | 911 |
|
|
2023
Q1 | $19.1K | Sell |
250
-473
| -65% | -$39.2K | ﹤0.01% | 822 |
|
|
2022
Q4 | $60K | Buy |
723
+381
| +111% | +$30.8K | 0.01% | 542 |
|
|
2022
Q3 | $27K | Sell |
342
-33
| -9% | -$2.78K | ﹤0.01% | 671 |
|
|
2022
Q2 | $28K | Sell |
375
-32
| -8% | -$2.4K | ﹤0.01% | 665 |
|
|
2022
Q1 | $37K | Sell |
407
-47
| -10% | -$4.34K | 0.01% | 623 |
|
|
2021
Q4 | $51K | Sell |
454
-182
| -29% | -$22K | 0.01% | 569 |
|
|
2021
Q3 | $80K | Sell |
636
-2,871
| -82% | -$370K | 0.01% | 494 |
|
|
2021
Q2 | $475K | Buy |
3,507
+28
| +0.8% | +$3.68K | 0.08% | 187 |
|
|
2021
Q1 | $472K | Buy |
3,479
+1,016
| +41% | +$152K | 0.09% | 171 |
|
|
2020
Q4 | $347K | Buy |
2,463
+853
| +53% | +$109K | 0.07% | 198 |
|
|
2020
Q3 | $179K | Buy |
1,610
+1,063
| +194% | +$119K | 0.04% | 248 |
|
|
2020
Q2 | $61K | Buy |
547
+321
| +142% | +$31.6K | 0.02% | 391 |
|
|
2020
Q1 | $18K | Sell |
226
-2,091
| -90% | -$185K | 0.01% | 304 |
|
|
2019
Q4 | $219K | Sell |
2,317
-140
| -6% | -$12.1K | 0.1% | 142 |
|
|
2019
Q3 | $185K | Sell |
2,457
-5
| -0.2% | -$416 | 0.1% | 143 |
|
|
2019
Q2 | $211K | Buy |
2,462
+60
| +2% | +$5.12K | 0.11% | 135 |
|
|
2019
Q1 | $217K | Buy |
2,402
+125
| +5% | +$10.6K | 0.13% | 116 |
|
|
2018
Q4 | $163K | Buy |
2,277
+1,500
| +193% | +$121K | 0.12% | 121 |
|
|
2018
Q3 | $74K | Hold |
777
| – | – | 0.04% | 185 |
|
|
2018
Q2 | $74K | Buy |
777
+160
| +26% | +$14.7K | 0.04% | 200 |
|
|
2018
Q1 | $54K | Sell |
617
-50
| -7% | -$4.57K | 0.03% | 222 |
|
|
2017
Q4 | $57K | Sell |
667
-121
| -15% | -$10.1K | 0.04% | 209 |
|
|
2017
Q3 | $68K | Buy |
788
+250
| +46% | +$20K | 0.04% | 211 |
|
|
2017
Q2 | $42K | Buy |
538
+221
| +70% | +$15.7K | 0.03% | 251 |
|
|
2017
Q1 | $22K | Buy |
317
+290
| +1,074% | +$19.5K | 0.02% | 311 |
|
|
2016
Q4 | $2K | Buy |
+27
| New | +$1.67K | ﹤0.01% | 615 |
|
Other funds holding XBI
Creative Financial Designs's XBI Position: Q1 2026 in Review
Creative Financial Designs increased its State Street SPDR S&P Biotech ETF (XBI) stake by 24% in Q1 2026, buying an estimated $9.74K and bringing the position to 397 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #890.
Creative Financial Designs first reported a position in XBI in Q4 2016 and has held it in 36 quarters since. The position peaked at $475K in Q2 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Creative Financial Designs held 397 shares of State Street SPDR S&P Biotech ETF worth $50.8K as of Q1 2026.
- Creative Financial Designs bought 78 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $9.74K.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Creative Financial Designs's portfolio in Q1 2026, its #890 holding.
- Creative Financial Designs first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 36 quarters since.
- Creative Financial Designs's State Street SPDR S&P Biotech ETF position peaked at $475K in Q2 2021.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Creative Financial Designs's 13F filing for Q1 2026, filed 13 Apr 2026.